Literature DB >> 17593365

Prostaglandin E(2) receptors in bone formation.

M Li1, D D Thompson, V M Paralkar.   

Abstract

Prostaglandins, PGE(2) in particular, have diverse actions on various organs, including inflammation, bone healing, bone formation, embryo implantation, induction of labour and vasodilatation, among others. However, systemic side effects have limited their clinical utility. The pharmacological activities of PGE(2) are mediated through four G protein-coupled receptor subtypes, EP1-EP4. Recent studies have shown that EP2 and EP4 receptors play important roles in regulating bone formation and resorption. EP2 and EP4 receptor-selective agonists have been shown to stimulate local or systemic bone formation, augment bone mass and accelerate the healing of fractures or bone defects in animal models upon local or systemic administration, thus, potentially offering new therapeutic options for enhancing bone formation and bone repair in humans. This review will focus on the studies related to bone formation and bone healing in the EP receptor knockout (KO) mice and the EP2 or EP4 receptor-selective agonist treated animal models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593365      PMCID: PMC2266676          DOI: 10.1007/s00264-007-0406-x

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  23 in total

1.  Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice.

Authors:  C Miyaura; M Inada; T Suzawa; Y Sugimoto; F Ushikubi; A Ichikawa; S Narumiya; T Suda
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

2.  Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.

Authors:  Keiji Yoshida; Hiroji Oida; Takuya Kobayashi; Takayuki Maruyama; Masaharu Tanaka; Teruaki Katayama; Kojiro Yamaguchi; Eri Segi; Tadao Tsuboyama; Mutsumi Matsushita; Kosei Ito; Yoshiaki Ito; Yukihiko Sugimoto; Fumitaka Ushikubi; Shuichi Ohuchida; Kigen Kondo; Takashi Nakamura; Shuh Narumiya
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

3.  Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice.

Authors:  M Li; D R Healy; Y Li; H A Simmons; D T Crawford; H Z Ke; L C Pan; T A Brown; D D Thompson
Journal:  Bone       Date:  2005-07       Impact factor: 4.398

4.  Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice.

Authors:  M P Akhter; D M Cullen; G Gong; R R Recker
Journal:  Bone       Date:  2001-08       Impact factor: 4.398

5.  Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis.

Authors:  Emi Kamoshita; Yasuhiro Ikeda; Mamoru Fujita; Hideki Amano; Atsuhiko Oikawa; Tastunori Suzuki; Yasuhumi Ogawa; Shohei Yamashina; Sadahiro Azuma; Shuh Narumiya; Nobuya Unno; Masataka Majima
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

6.  Effects of selective prostaglandin EP2 and EP4 receptor agonists on bone resorption and formation in fetal rat organ cultures.

Authors:  Lawrence G Raisz; Florence N Woodiel
Journal:  Prostaglandins Other Lipid Mediat       Date:  2003-07       Impact factor: 3.072

7.  Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats.

Authors:  Masahiro Tanaka; Akinori Sakai; Soshi Uchida; Shinya Tanaka; Masato Nagashima; Teruaki Katayama; Kojiro Yamaguchi; Toshitaka Nakamura
Journal:  Bone       Date:  2004-06       Impact factor: 4.398

8.  Local stimulation of new bone formation by prostaglandin E1: quantitative histomorphometry and comparison of delivery by minipumps and controlled-release pellets.

Authors:  S C Miller; S C Marks
Journal:  Bone       Date:  1993 Mar-Apr       Impact factor: 4.398

9.  An EP2 receptor-selective prostaglandin E2 agonist induces bone healing.

Authors:  V M Paralkar; F Borovecki; H Z Ke; K O Cameron; B Lefker; W A Grasser; T A Owen; M Li; P DaSilva-Jardine; M Zhou; R L Dunn; F Dumont; R Korsmeyer; P Krasney; T A Brown; D Plowchalk; S Vukicevic; D D Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

10.  A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing.

Authors:  Mei Li; Hua Zhu Ke; Hong Qi; David R Healy; Yan Li; D Todd Crawford; Vishwas M Paralkar; Thomas A Owen; Kimberly O Cameron; Bruce A Lefker; Thomas A Brown; David D Thompson
Journal:  J Bone Miner Res       Date:  2003-11       Impact factor: 6.741

View more
  26 in total

1.  In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.

Authors:  S Hu; C C Liu; G Chen; T Willett; R N Young; M D Grynpas
Journal:  Osteoporos Int       Date:  2015-08-14       Impact factor: 4.507

2.  Biological aspects of bone, cartilage and tendon regeneration.

Authors:  Marko Pecina; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2007-08-18       Impact factor: 3.075

3.  [Heterotopic ossifications in total hip arthroplasty: prophylaxis and therapy].

Authors:  J Schauwecker; F Pohlig; A Toepfer; H Gollwitzer; R von Eisenhart-Rothe
Journal:  Orthopade       Date:  2011-06       Impact factor: 1.087

4.  Osteogenic differentiation is synergistically influenced by osteoinductive treatment and direct cell-cell contact between murine osteoblasts and mesenchymal stem cells.

Authors:  Ming-Tzu Tsai; Dan-Jae Lin; Sherry Huang; Hsiu-Ting Lin; Walter H Chang
Journal:  Int Orthop       Date:  2011-05-13       Impact factor: 3.075

Review 5.  Osteocytic signalling pathways as therapeutic targets for bone fragility.

Authors:  Lilian I Plotkin; Teresita Bellido
Journal:  Nat Rev Endocrinol       Date:  2016-05-27       Impact factor: 43.330

Review 6.  Anabolic agents and bone quality.

Authors:  Tarek Sibai; Elise F Morgan; Thomas A Einhorn
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

7.  Age-related changes in bone morphology are accelerated in group VIA phospholipase A2 (iPLA2beta)-null mice.

Authors:  Sasanka Ramanadham; Kevin E Yarasheski; Matthew J Silva; Mary Wohltmann; Deborah Veis Novack; Blaine Christiansen; Xiaolin Tu; Sheng Zhang; Xiaoyong Lei; John Turk
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

8.  Anabolic effects of PTH in cyclooxygenase-2 knockout osteoblasts in vitro.

Authors:  Shilpa Choudhary; Hechang Huang; Lawrence Raisz; Carol Pilbeam
Journal:  Biochem Biophys Res Commun       Date:  2008-05-21       Impact factor: 3.575

Review 9.  Prostaglandins in bone: bad cop, good cop?

Authors:  Katherine A Blackwell; Lawrence G Raisz; Carol C Pilbeam
Journal:  Trends Endocrinol Metab       Date:  2010-01-14       Impact factor: 12.015

10.  KMN-159, a novel EP4 receptor selective agonist, stimulates osteoblastic differentiation in cultured whole rat bone marrow.

Authors:  Thomas A Owen; Chandni Patel; Shanqiao Wei; Chi S Ho; Kaylah Birmingham; Samuel Sanchez; Natalie Chung; Alexa Cahill; James P O'Malley; Stephen D Barrett; María Inés Morano
Journal:  Gene       Date:  2020-04-22       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.